The European Union's drugs regulator on Thursday said it recommends approval of Eisai and Biogen's Leqembi in patients with early Alzheimer's disease, months after the agency first rejected the treatment.

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug

The European Union's drugs regulator reversed its decision to block the Alzheimer's drug lecanemab, a treatment aimed at slowing cognitive decline in patients. In July, the Amsterdam-based European Medicines Agency (EMA) denied recommending approval of the drug made by Eisai and Biogen because it considered the risks - especially bleeding and swelling in the brain - to be greater than the potential benefits in a broad population.

Google will stop serving political advertisements in the European Union. The decision, announced in The Keyword blog, is in response to an upcoming new rule for the bloc that "introduces significant new operational challenges and legal uncertainties for political advertisers and platforms.

Google has dropped political ads in response to regulations adopted by France, Canada, and Brazil, and now it says the EU is next.